论文部分内容阅读
[目的]探讨米非司酮保守性治疗围绝经期子宫肌瘤的疗效及影响因素.[方法]收集2010年12月至2016年6月在本院接受治疗的子宫肌瘤患者40例,采用米非司酮治疗,比较治疗前后子宫肌瘤的体积变化,分析米非司酮治疗效果的影响因素.[结果]治疗后子宫肌瘤体积明显缩小(P6个月及肌瘤位置位于浆膜下的患者,米非司酮治疗效果较差(P0.05);多因素Logistic回归分析显示,ER受体、肌瘤大小、病程是影响因素米非司酮治疗效果的独立风险因素(P<0.05).[结论]米非司酮保守性治疗子宫肌瘤疗效显著,而ER受体、肌瘤大小及病程是影响到米非司酮治疗效果的主要因素.“,”[Objective]To investigate the clinical effect of mifepristone in the treatment of uterine fibroids and its influencing factors.[Methods]Forty patients with myoma of uterus treated in our hospital from December 2010 to June 2016 were selected;Mifepristone was used to compare the volume change of hysteromyoma before and after treatment,and the factors influencing the effect of mifepristone treatment were analyzed.[Results]The volume of myoma of uterus decreased significantly after treatment (P6 months and the fibroids located under the serosa(P<0.05).[Conclusion]Mifepristone is effective in the treatment of uterine fibroids;ER receptor,myoma size and course of disease are the main factors that influence the effect of mifepristone treatment.